AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$PHVS

Lesage Anne sold $1.1M of PHVS

Lesage Anne (Chief Early Development) sold 30,000 shares of Pharvaris N.V. (PHVS) at $38.30 ($1.15M total) on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lesage Anne
Published Sep 14, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 4:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, potentially influencing short-term price action.

02

Market read

New insider sale may prompt traders to reassess PHVS's short-term outlook.

03

What to watch

Insider's 10b5-1 plan pre-arranged the sale, reducing informational value.

Relevance 5/10Novelty 8/10Timing: filing today

Background

SEC Form 4 filing reports an insider transaction for Pharvaris.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Chief Early Development officer Lesage Anne sold 30,000 shares of Pharvaris (PHVS) for $1.149M on Sep 10, 2026.

Expected impact

Possible short-term dip of 2-3% as market digests the sale.

Evidence & confidence

Officer-level insider sold a sizable block, indicating possible concerns, but the amount is modest relative to market cap.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale may be routine portfolio rebalancing, not a bearish signal.

Key entities

  • person
    Lesage Anne

    Chief Early Development officer at Pharvaris

  • company
    Pharvaris N.V.

    Biotech company listed on Nasdaq under PHVS

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min